• We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.
  • We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.
  • We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.
  • We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.

Partnering

OncoMark PartneringOncoMark has invested in R&D and in-licensing of IP for diagnostic assay development. We believe that partnering should begin as early as possible in the development process.

Every winning partnership starts with a simple decision Click for more details »

 Products

IHC-Mark and Biomarker Interpretation Workflow 
OncoMark's lead product in development is OncoMasTR,
a novel prognostic assay for early breast cancer. 

This multi-biomarker panel will determine the risk of recurrence for early breast cancer patients as either high or low risk.

The assay will aid the clinicians to determine the best option treatments for their patients
 
View current products »
 

Research Projects



 

 

Subscribe to RSS FeedCompany News

November 2015 - OncoMark featured in The Sunday Times
OncoMark's CEO Mr Desmond O'Leary was interviewed for the Sunday Times » read more
April 2016 - OncoMasTR assay for breast cancer featured in the Irish Examiner
The Irish Examiner interviews OncoMark's Chief Scientific Officer about the OncoMasTR assay for breast cancer » read more
April 2016 - OncoMasTR assay for breast cancer featured in the Medical Independent
Prof. William Gallagher describes the OncoMasTR assay for breast cancer in the Medical Independent » read more
September 2015 - OncoMark profiled in 'Ones to Watch' article in Business & Finance
OncoMark have been profiled in the 'Ones to Watch' feature in Business & Finance » read more
September 2015 - OncoMark are awarded €2.7 million by the European Commission to develop a diagnostic assay for breast cancer
 OncoMark are pleased to announce they have been awarded €2.7 million by the European Commission, for the commercial development of a new Diagnostic test for breast cancer patients. » read more

Vacancies

June 2016 - Biostatistician vacancy
OncoMark are seeking to recruit a full-time Biostatistician to use statistics to help guide the design of a new multi-gene Cancer Diagnostic test, by determination of key parameters of the final diagnostic assay. » read more